{
    "nctId": "NCT03850873",
    "briefTitle": "A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics",
    "officialTitle": "A Phase I Clinical\uff0c Tolerance and Pharmacokinetic Evaluation of 1 Schedules of Oral TQB3616\uff0cA Cyclin-Dependent Kinase Inhibitor \uff0cIn Patients With Advanced Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "DLT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. \u226518 years old\n2. Patients definitely diagnosed by pathology and/or cytology as advanced breast cancer with ER+\u3001Her2-,who failed with standard endocrine therapy.\n3. ECOG PS:0-1,Survival is expected to be greater than 3 months\n4. Main organs function is normal or must meet the following criteria(within past 14 days) 1) hemoglobin\u226590g/L; neutrophils\u22651.5 x109/L; Platelets\u2265100 x109/L 2)Albumin\u226529g/L; total bilirubin \u2264 1.5 x upper limit of normal (ULN); aspartic transaminase(AST) and alanine transaminase(ALT)\u22642.5 ULN, and \u2264 5 x ULN with hepatic metastasis;serum creatinine \u22641.5 xULN\uff0ccreatinine clearance \\>60ml/min; Triglyceride\u22643.0mmol/L, cholesterol\u22647.75mmol/L\n\n3)Doppler ultrasound evaluation: Left ventricular ejection fraction(LVEF)\u226550% 5.Patients should be voluntary and sign the informed consent before taking part in the study\n\nExclusion Criteria:\n\n1. Patients with malignant tumors, except for Cured cutaneous basal cell carcinoma and cervical carcinoma in situ\n2. Prior treatment with chemotherapy with cytotoxic drugs within 4 weeks, mitomycin C or nirtosocarbamide within 8 weeks\n3. Prior treatment with any anti-cancer therapy including hormone therapy radioimmunotherapy, molecular targeted therapy, immunotherapy or other biological therapy with 2 weeks\n4. Patients treated with other CDK4/6 inhibitors;\n5. Patients with brain metastasis, spinal cord compression, cancerous meningitis, CT or MRI examination reminds patients with cerebral or soft meningeal diseases in the screening phase;\n6. Previous history of stem cell or bowe marrow transplant;\n7. A variety of factors that affect oral medication (such as inability to swallow, gastrointestinal resection, intestinal obstruction, etc.)\n8. Patients with non-healing wounds or fractures, except for bone metastatics with pathologic frature\n9. Previous history of uncontrolled cardiovascular disease including: a) Grade 3 or higher congestive heart failure (NYHA Classification);b)unstable angina pectoris or newly developped angina pectoris within 3months before the trial; c) Myocardial in farction or stroke occured within 6 months prior to intiation of trial; d) Arrhythmias requiring antiarrhythmic treatment(beta-blocker or digoxin is permitted)\n10. Patients who need to take CYP3A4 inhibitors or inducers from the screening period;\n11. Patients with drug abuse history or unable to get rid of drugs or Patients with mental disorders\n12. Patients with the urine protein\u22652+, total ammount of 24 hours urinary protein determination\\>1.0 grams;\n13. Patients with hyperactive/venous thrombosis events within 6 months,such as cerebrovascular accidents (including temporary ischemic attack), deep venous thrombosis and pulmonary embolism\n14. Patients with active hepatitis b or c infection\n15. Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history;\n16. Patients allergic to TQB3616 or any adjuvant in the capsule\n17. Patients who took part in other trials within 4 weeks;\n18. Patients with concomitant diseases which could seriously endanger themselves or those who won't complete the study according to investigators;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}